AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Matrix metalloproteinase inhibitors to treat tuberculosis

Summary

Tuberculosis is an airborne bacterial infection that capitalizes on enzymes produced by the body’s immune system to destroy lung tissue. In particular, the bacteria take advantage of the natural secretion of matrix metalloproteinases (MMPs), which degrade lung tissue and inadvertently facilitate bacterial proliferation. Current tuberculosis treatments consist primarily of antibiotic administration, but are often ineffective in the long term. This technology is an MMP inhibitor that aims to treat tuberculosis by preventing the degradation of lung tissue and subsequent growth of bacteria.

Technology Benefits

Reduces lung damage due to tuberculosisHinders proliferation of tuberculosis-causing bacteria in infected tissuePatent Information:Patent Pending (US 20140199289)Tech Ventures Reference: IR 2910

Technology Application

Tuberculosis therapyTherapy for patients with antibiotic-resistant tuberculosisTherapy for other diseases in which MMPs are implicated in tissue degradation

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here